Skip to main content

What the FDA labels say about taking them together

Albumin aggregated and pentetic acid

Albumin aggregated's FDA label (Draximage Maa) of February 13, 2024 names pentetic acid in its contraindications section; the pentetic acid label PlainMeds reads does not name albumin aggregated. The albumin aggregated label: “DRAXIMAGE MAA is contraindicated in patients with severe pulmonary hypertension.”

Check it at the source: the albumin aggregated FDA label on DailyMed (effective October 13, 2025); the pentetic acid FDA label on DailyMed (effective May 8, 2023).

What does the albumin aggregated label say about pentetic acid?

Draximage Maa label (Jubilant DraxImage Inc, February 13, 2024), contraindications

CONTRAINDICATIONS DRAXIMAGE MAA is contraindicated in patients with: Severe pulmonary hypertension [see Warnings and Precautions (5.1)].

Source: FDA drug label (Draximage Maa, BLA017881), Jubilant DraxImage Inc, effective February 13, 2024 (SPL set bbefaa05-1dc0-3ae7-7264-ce1eddf0da2b), via openFDA

Source: FDA drug label (Pulmotech MAA), Curium US LLC, effective October 13, 2025 (SPL set a8b7adf0-2c6b-4acd-96d3-a099306951a0), via openFDA; the full label on DailyMed

What does the pentetic acid label say about albumin aggregated?

Pentetic acid's label (effective May 8, 2023) does not name albumin aggregated in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (DRAXIMAGE DTPA), Jubilant DraxImage Inc., dba Jubilant Radiopharma, effective May 8, 2023 (SPL set becdab53-f7a7-7280-6930-21f3a61b99e7), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Albumin aggregated generic labelers
1Pentetic acid generic labelers
Albumin aggregatedPentetic acid
Labeled forn/an/a
Boxed warningNoNo
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?